S&P 500
(0.18%) 5 109.31 points
Dow Jones
(0.15%) 38 298 points
Nasdaq
(0.20%) 15 960 points
Oil
(-1.09%) $82.94
Gas
(4.94%) $2.02
Gold
(0.10%) $2 349.50
Silver
(0.16%) $27.58
Platinum
(4.14%) $960.30
USD/EUR
(-0.18%) $0.933
USD/NOK
(-0.31%) $10.99
USD/GBP
(-0.46%) $0.797
USD/RUB
(1.74%) $93.47

实时更新: Amphastar Pharmaceuticals [AMPH]

交易所: NASDAQ 部门: Healthcare 工业: Drug Manufacturers—Specialty & Generic
BUY
100.00%
return 4.23%
SELL
50.00%
return -2.48%
最后更新时间29 Apr 2024 @ 23:45

1.31% $ 41.65

出售 109429 min ago

@ $55.32

发出时间: 14 Feb 2024 @ 00:06


回报率: -24.70%


上一信号: Feb 13 - 22:30


上一信号: 购买


回报率: 0.69 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:45):

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France...

Stats
今日成交量 95 427.00
平均成交量 419 558
市值 2.04B
EPS $0 ( 2024-02-27 )
下一个收益日期 ( $0 ) 2024-05-07
Last Dividend $0.300 ( 2010-06-11 )
Next Dividend $0 ( N/A )
P/E 16.02
ATR14 $0.0430 (0.10%)
Insider Trading
Date Person Action Amount type
2024-04-01 Petersen Floyd F. Sell 500 Common Stock
2024-03-15 Zhang Jack Y. Buy 722 046 Common Stock
2024-03-15 Zhang Jack Y. Sell 408 721 Common Stock
2024-03-17 Zhang Jack Y. Sell 15 768 Common Stock
2024-03-15 Zhang Jack Y. Buy 310 930 Common Stock
INSIDER POWER
-2.74
Last 100 transactions
Buy: 1 574 905 | Sell: 1 727 474

Amphastar Pharmaceuticals 相关性

10 最正相关
LMNR0.96
PDFS0.955
RCEL0.953
GEOS0.953
ALTR0.951
VTYX0.951
ERII0.95
SLMBP0.95
PANL0.946
ANSS0.945
10 最负相关
CSSEP-0.95
NAKD-0.95
ALXO-0.95
MICS-0.95
BLUE-0.946
CBNK-0.944
PMVP-0.943
CMLS-0.94
BWB-0.94
FGBI-0.939

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Amphastar Pharmaceuticals 财务报表

Annual 2023
营收: $644.40M
毛利润: $343.97M (53.38 %)
EPS: $2.85
FY 2023
营收: $644.40M
毛利润: $343.97M (53.38 %)
EPS: $2.85
FY 2022
营收: $498.99M
毛利润: $248.86M (49.87 %)
EPS: $1.880
FY 2021
营收: $437.77M
毛利润: $199.74M (45.63 %)
EPS: $1.350

Financial Reports:

No articles found.

Amphastar Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Amphastar Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.09 - Potential for dividend initiation, but uncertain (18.12%)
Information
First Dividend $0.300 2009-06-11
Last Dividend $0.300 2010-06-11
Next Dividend $0 N/A
Payout Date 2010-06-30
Next Payout Date N/A
# dividends 2 --
Total Paid Out $0.600 --
Avg. Dividend % Per Year 0.00% --
Score 2.66 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.09
Div. Directional Score 7.14 --
Next Divdend (Est)
(2025-03-28)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
2.66
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2009 $0 0.00%
2010 $0 0.00%
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2131.5005.738.60[0 - 0.5]
returnOnAssetsTTM0.09091.2006.978.36[0 - 0.3]
returnOnEquityTTM0.2321.5008.5310.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM2.170.8004.143.31[1 - 3]
quickRatioTTM1.6600.8004.943.95[0.8 - 2.5]
cashRatioTTM0.6411.5007.5510.00[0.2 - 2]
debtRatioTTM0.392-1.5003.46-5.19[0 - 0.6]
interestCoverageTTM9.501.0007.597.59[3 - 30]
operatingCashFlowPerShareTTM3.832.008.7210.00[0 - 30]
freeCashFlowPerShareTTM3.032.008.4810.00[0 - 20]
debtEquityRatioTTM0.928-1.5006.29-9.43[0 - 2.5]
grossProfitMarginTTM0.5411.0004.324.32[0.2 - 0.8]
operatingProfitMarginTTM0.2941.0006.126.12[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3091.0009.399.39[0.2 - 2]
assetTurnoverTTM0.4260.800-0.494-0.395[0.5 - 2]
Total Score10.19

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM14.331.0008.650[1 - 100]
returnOnEquityTTM0.2322.509.0610.00[0.1 - 1.5]
freeCashFlowPerShareTTM3.032.008.9910.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM3.832.008.7210.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.1911.500-2.060[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2851.0005.380[0.1 - 0.5]
Total Score4.09

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。